The abstract is read at the publisher; the summary is JClub's.
Genetic disruption of cullin-5 (CUL5) CRL5 ubiquitin ligase components preserves T-cell cytotoxicity during repeated tumor challenge, maintaining function under repetitive antigen stimulation.
- Why it matters: Adoptive T-cell therapies need cytotoxic activity to persist for as long as tumors remain, but repetitive antigen stimulation can act as an intrinsic brake on T-cell function.
- What they did: Two studies converge on a ubiquitin-dependent pathway centered on the CUL5-RING E3 ligase complex, using genetic disruption of CRL5 components and, separately, pharmacologic inhibition of CRL5 and related ubiquitin ligase complexes.
- The result: Targeting CRL5 preserves cytotoxicity during repeated tumor challenge and extends benefits across multiple antigens and receptor architectures, suggesting improved functional persistence and therapeutic durability.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.